Owkin Announces Partnership with AstraZeneca to Develop an AI gBRCA Pre-Screen Solution for Breast Cancer

Utilizing Owkin’s expansive data network and cutting-edge AI, this solution optimizes pre-screening for gBRCA mutations in breast cancer directly from digitized H&E pathology slidesThe solution aims to improve gBRCA identification and expand access to novel treatment optionsThis tool will be developed using high-quality data from more than 6,500 whole slide images (WSI) from resections and biopsies of approximately 2,000 patients, up to half of which have the gBRCA mutation, to ensure robust performance across multiple laboratory settings

Owkin, the first end-to-end AI-biotech that uses cutting-edge causal AI to unlock precision drug discovery, development and diagnostics, is pleased to announce a new partnership with AstraZeneca, a global biopharmaceutical company, to develop an AI-powered tool to pre-screen for gBRCA mutations (gBRCAm) in breast cancer directly from digitized pathology slides. As part of Owkin’s ongoing collaboration with Gustave Roussy and The Centre Léon Bérard through PortrAIt, a French consortium to accelerate precision medicine through AI-enabled digital pathology, this tool aims to significantly accelerate and expand access to gBRCA testing that too many patients may not be considered for.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241002556572/en/

Thomas Clozel, MD, CEO of Owkin, said: "We are excited to collaborate with AstraZeneca to bring the benefits of AI to BRCA testing with the gBRCA Pre-Screen solution. During Breast Cancer Awareness Month, it's especially important to highlight how by streamlining the diagnostic process for determining BRCA mutation status, we can expand access to BRCA testing and identify more gBRCAm patients more rapidly. Our goal is to generate the best possible medical evidence through multiple clinical studies, making genetic testing more accessible and precise, and therefore reduce the inequity of care by allowing more patients to benefit from tailored care."

BRCA testing, which identifies mutations in the BRCA1 and BRCA2 genes, plays a vital role in determining an individual's risk for developing certain cancers, including breast and ovarian cancers. Knowing the BRCA status of breast cancer patients is important to help identify familial risk and guide treatment options, including responses to targeted therapies. While many professional bodies have released guidelines recommending broader BRCA testing, it is not always consistently offered to eligible individuals, and implementation varies between countries. This is causing an inadvertent exclusion of individuals who may benefit from these tests. If routinely used, this gBRCA pre-screening solution could lead to the identification of thousands more gBRCAm HR-positive early breast cancer patients in France, Germany, Italy, Spain, and the United Kingdom by 2030.

Kristina Rodnikova, Head of Global Commercial Diagnostics, Oncology at AstraZeneca, said: "On average, a woman with a BRCA1 or BRCA2 gene mutation has up to a 7 in 10 chance of being diagnosed with breast cancer by age 80. This collaboration with Owkin underscores our commitment to advancing precision medicine, helping address the unmet need and identifying patients at risk of harboring BRCA mutations to improve their outcomes.”

The typical BRCA testing journey for a patient can take several months and involve several healthcare professionals, from initial consultation to results, strongly impacting the patient's outcomes. The gBRCA pre-screening solution has the potential to significantly enhance the efficiency of BRCA mutation identification. In less than one hour, the solution could identify a patient at high risk of harboring gBRCA mutation by leveraging existing material, including H&E slides. This could greatly streamline the gBRCA testing process, allowing oncologists and genetic counsellors to accelerate the gBRCA genetic testing for high-risk patients and incorporate these genetic test results into the treatment planning process without delays.

The solution is currently in development and undergoing validation.

About Owkin

Owkin is the first end-to-end AI biotech company on a mission to understand complex biology and ensure every patient gets the right treatment. We identify precision therapeutics, de-risk and accelerate clinical trials and develop diagnostics using AI trained on world-class patient data through privacy-enhancing technologies. We merge wet lab experiments with advanced AI techniques to create a powerful feedback loop for accelerated discovery and innovation in oncology, cardiovascular, immunity and inflammation. Owkin also founded MOSAIC, the world’s largest spatial multi-omics atlas for cancer research across seven cancer indications. Owkin has raised over $300 million through investments from leading biopharma companies, including Sanofi and BMS, and venture funds like F-Prime, GV and Bpifrance, among others.

About PortrAIt

PortrAIt is a landmark French government-endorsed program to structure and scale the digital pathology ecosystem in France to augment and improve the diagnosis of cancer. The consortium brings together 6 partners from the public and private sectors. PortrAIt will enable pathology labs and research hospitals to work with technology pioneers to develop and deploy AI tools for digital pathology.

PortrAIt project was financed by the government within the framework of France 2030 and by the European Union - Next Generation EU within the framework of the France Relance Plan.

View source version on businesswire.com: https://www.businesswire.com/news/home/20241002556572/en/